Your email has been successfully added to our mailing list.

×
0.0154193305754043 0.0154193305754043 0.0154193305754043 0.0154193305754043 0.0154193305754043 0.0154193305754043 0.0154193305754043 0.0154193305754043
Stock impact report

Martin Pharmaceuticals Secures Exclusive Rights From Mitsubishi Tanabe Pharma for Docarpamine to Treat Decompensated Chronic Liver Disease Including Ascites [Yahoo! Finance]

MITSUBISHI CH GRP U/ADR (MTLHY) 
NASDAQ:AMEX Investor Relations: mitsubishichem-hd.co.jp/english/ir
Company Research Source: Yahoo! Finance
treatment of complications arising from advanced liver disease, today announced that it has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for exclusive access to docarpamine-related toxicology, preclinical, clinical safety, and pharmacokinetics data in the field of gastrointestinal conditions, including ascites, for use outside of Japan and China . Under the terms of the agreement, MTPC will receive an undisclosed upfront payment and additional milestones and royalties. "This license agreement with MTPC, a global leader in the pharmaceutical industry, will help us rapidly advance the development of CIQUAAX," said Sven Jacobson , Chief Executive Officer of Martin Pharmaceuticals. "We are grateful to be able to access MTPC's years of experience with docarpamine and are excited by the potential of CIQUAAX given the significant unmet need for a safe and effective therapy for patients with decompensated chronic liver disease." This announcement follo Show less Read more
Impact Snapshot
Event Time:
MTLHY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
MTLHY alerts

from News Quantified
Opt-in for
MTLHY alerts

from News Quantified